Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Asterias Biotherapeutics, Inc.AST · Entity 159180 | Director | June 21, 2018 | June 25, 2018 |
| DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930 | Director | May 26, 2022 | May 27, 2022 |
| Prestige Consumer Healthcare Inc.PBH · Entity 4350 | Director | August 01, 2023 | August 03, 2023 |
| RAPID MICRO BIOSYSTEMS, INC.RPID · Entity 6966 | Director | February 27, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Asterias Biotherapeutics, Inc.
Report date June 21, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-21 | Direct | 20,000 |
Reported balance
After 2018-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-21 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2026-02-28 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 20,000 |
| Series A Common StockSEC Table I · non-derivative | Direct | 19,706 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 19,706 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2027-03-29 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 20,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2020-03-31 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 20,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2019-03-31 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 20,000 |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $4.37 · Expires 2021-05-13 | Direct | 7,353 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 7,353 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors.
DYNAVAX TECHNOLOGIES CORP
Report date May 26, 2022 · Filed May 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 5,357 |
Reported balance
After 2022-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 5,357 · Balance 5,357 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.68 · Expires 2029-05-25 | Direct | 22,500 |
Reported balance
After 2022-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-26 · Grant · Acquired 22,500 · Balance 22,500 F3: Not applicable. F2: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company.
F2: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.
F3: Not applicable.
Prestige Consumer Healthcare Inc.
Report date August 01, 2023 · Filed August 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 27,098 |
Reported balance
After 2023-08-01 transaction · row 1
1 source rowRow 1 · 2023-08-01 · Grant · Acquired 2,295 · Balance 27,098 F1: The Reporting Person received 2,295 restricted stock units equal to $150,000 divided by the closing stock price of $65.37 on August 1, 2023, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received 2,295 restricted stock units equal to $150,000 divided by the closing stock price of $65.37 on August 1, 2023, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.
RAPID MICRO BIOSYSTEMS, INC.
Report date February 27, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 29,442 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Exercise / conversion · Acquired 842 · Balance 29,442 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2026-03-10 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Exercise / conversion · Disposed 842 · Balance 0 F1: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PFIZER INC
Report date March 31, 2011 · Filed April 04, 2011
Section 16 reporting ended · disclosed 2011-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 34,248 |
Reported balance
After 2011-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2011-03-31 · Grant · Acquired 69 · Balance 34,248 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 2, 2026 18:11 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Exercise / conversionStock Option (Right to Buy) · Derivative | 842 | $0.75 Strike: $0.75 | $631.50 |
DisclosureSEC source: 0001107158-26-000002 · wk-form4_1772493071.xml · derivative · entry 2 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 842 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 18:11 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Exercise / conversionClass A Common Stock | 842 | $0.75 | $631.50 |
DisclosureSEC source: 0001107158-26-000002 · wk-form4_1772493071.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:07 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001380106-25-000127 · wk-form4_1748390841.xml · derivative · entry 2 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Underlying: Class A Common Stock · 28,650 shares Expires 2035-05-21 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:07 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-25-000127 · wk-form4_1748390841.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,600 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 19:08 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001380106-24-000150 · wk-form4_1716937708.xml · derivative · entry 2 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Underlying: Class A Common Stock · 28,650 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 19:08 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-24-000150 · wk-form4_1716937708.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 14:02 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 2,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-087191 · tm2322776-5_4seq1.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,098 F1 · shares: The Reporting Person received 2,295 restricted stock units equal to $150,000 divided by the closing stock price of $65.37 on August 1, 2023, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control. Read SEC document |
| May 04, 2023 Filed May 5, 2023 18:09 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001380106-23-000083 · wf-form4_168332456471384.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 17:17 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 2,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-085709 · tm2222537-3_4seq1.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,803 F1 · shares: The Reporting Person received 2,495 restricted stock units (equal to $150,000 divided by the closing stock price of $60.12 on August 2, 2022) in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii) change in control. Read SEC document |
| May 26, 2022 Filed May 27, 2022 17:00 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $11.68 | Not disclosed |
DisclosureSEC source: 0001209191-22-032608 · doc4.xml · derivative · entry 2 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-05-25 F3 · price: Not applicable. F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 17:00 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantRestricted Stock Unit · Derivative | 5,357 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032608 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,357 Underlying: Common Stock · 5,357 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company. Read SEC document |
| May 23, 2022 Filed Jun 10, 2022 18:33 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001127602-22-017270 · form4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Stock · 12,500 shares Expires 2032-05-22 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 19:00 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 2,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-100930 · tm2124298-2_4seq1.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,308 F1 · shares: The Reporting Person received 2,808 restricted stock units (equal to $150,000 divided by the closing stock price of $53.42 on August 3, 2021) in connection with the Issuer's director compensation program. The restricted stock units vest immediately upon grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii) change in control. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 20:03 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092762 · tm2122156-18_4seq1.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2031-07-13 F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 19:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-037426 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-27 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 28, 2022, on the one year anniversary of the grant date. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 17:22 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 3,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-091545 · tm2023357d3_4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 F1 · shares: The Reporting Person received 3,732 restricted stock units (equal to $145,000 divided by the closing stock price of $38.86 on August 4, 2020) in connection with the Issuer's director compensation program. The restricted stock units vest immediately upon grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii) change in control. Read SEC document |
| May 28, 2020 Filed May 29, 2020 16:41 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001209191-20-032963 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-27 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 28, 2021, on the one year anniversary of the grant date. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 16:30 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 4,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-037221 · tv526534_4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,768 F1 · shares: The Reporting Person received 4,183 restricted stock units (equal to $145,000 divided by the closing stock price of $34.67 on July 30, 2019) in connection with the Issuer's director compensation program. The restricted stock units vest immediately upon grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii) change in control. Read SEC document |
| May 30, 2019 Filed May 31, 2019 18:32 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $4.97 | Not disclosed |
DisclosureSEC source: 0001209191-19-033732 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-05-29 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 30, 2020, on the one year anniversary of the grant date. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 16:02 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 3,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-041354 · tv499909_4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,585 F1 · shares: The Reporting Person received 3,779 restricted stock units (equal to $135,000 divided by the closing stock price of $35.73 on July 31, 2018) in connection with the Issuer's director compensation arrangement. The restricted stock units vest immediately upon execution and acceptance of the award and shall be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of the Reporting Person's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the Reporting Person's Board membership ceases for reasons other than death or disability. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:50 UTC | Asterias Biotherapeutics, Inc. AST · Entity 159180 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-18-029809 · form4.xml · derivative · entry 2 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 17:12 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $15.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-034772 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-05-30 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 31, 2019, on the one year anniversary of the grant date. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 16:05 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | PurchaseCommon Stock, par value $0.01 per share | 3,000 | $37.04 | $111,120.00 |
DisclosureSEC source: 0001144204-18-006620 · tv485273_4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,806 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 15:32 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 2,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-040285 · v472278_4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,806 F1 · shares: The Reporting Person received 2,564 restricted stock units (equal to $135,000 divided by the closing stock price of $52.64 on August 1, 2017) in connection with the Issuer's director compensation arrangement. The restricted stock units vest immediately upon execution and acceptance of the award and shall be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of the Reporting Person's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the Reporting Person's Board membership ceases for reasons other than death or disability. Read SEC document |
| June 02, 2017 Filed Jun 2, 2017 18:12 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $5.90 | Not disclosed |
DisclosureSEC source: 0001209191-17-037429 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2024-06-01 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on June 2, 2018, on the one year anniversary of the grant date. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 17:06 UTC | Asterias Biotherapeutics, Inc. AST · Entity 159180 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001140361-17-014423 · form4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-03-29 F1 · security: The stock options vest over four equal quarterly installments beginning on March 31, 2017, contingent upon continued service on the Board of Directors. Read SEC document |
| March 31, 2011 Filed Apr 4, 2011 16:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 69 | $20.31 | $1,401.39 |
DisclosureSEC source: 0001225208-11-010802 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,248 Underlying: Common Stock · 69 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2011 Filed Mar 16, 2011 20:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 973 | $19.76 | $19,226.48 |
DisclosureSEC source: 0001225208-11-009809 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,179 Underlying: Common Stock · 973 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:45 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 7,724 | $19.24 | $148,609.76 |
DisclosureSEC source: 0001225208-11-007976 · doc4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,778 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 00:26 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 1,961 | $18.90 | $37,062.90 |
DisclosureSEC source: 0001225208-11-007693 · doc4.xml · nonDerivative · entry 3 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,502 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 00:26 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 5,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007693 · doc4.xml · nonDerivative · entry 2 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,463 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 00:26 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 10,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007693 · doc4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,951 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| December 31, 2010 Filed Jan 3, 2011 22:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 76 | $17.51 | $1,330.76 |
DisclosureSEC source: 0001225208-11-000281 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,897 Underlying: Common Stock · 76 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2010 Filed Dec 17, 2010 22:14 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 85 | $17.08 | $1,451.80 |
DisclosureSEC source: 0001225208-10-027429 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,821 Underlying: Common Stock · 85 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2010 Filed Dec 2, 2010 00:19 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 59 | $16.30 | $961.70 |
DisclosureSEC source: 0001225208-10-026045 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,736 Underlying: Common Stock · 59 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2010 Filed Nov 16, 2010 23:46 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 485 | $16.75 | $8,123.75 |
DisclosureSEC source: 0001225208-10-025025 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,677 Underlying: Common Stock · 485 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 29, 2010 Filed Nov 1, 2010 20:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 60 | $17.42 | $1,045.20 |
DisclosureSEC source: 0001225208-10-023833 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,192 Underlying: Common Stock · 60 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2010 Filed Oct 18, 2010 23:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 57 | $17.75 | $1,011.75 |
DisclosureSEC source: 0001225208-10-023192 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,132 Underlying: Common Stock · 57 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2010 Filed Oct 1, 2010 19:27 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 83 | $17.17 | $1,425.11 |
DisclosureSEC source: 0001225208-10-021679 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,075 Underlying: Common Stock · 83 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2010 Filed Sep 17, 2010 11:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 19 | $17.27 | $328.13 |
DisclosureSEC source: 0001225208-10-020976 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,992 Underlying: Common Stock · 19 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2010 Filed Sep 2, 2010 12:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 131 | $15.91 | $2,084.21 |
DisclosureSEC source: 0001225208-10-020184 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,973 Underlying: Common Stock · 131 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F1 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F1 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 13, 2010 Filed Aug 17, 2010 15:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 427 | $16.08 | $6,866.16 |
DisclosureSEC source: 0001225208-10-019321 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,842 Underlying: Common Stock · 427 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 30, 2010 Filed Aug 3, 2010 15:19 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 94 | $15.00 | $1,410.00 |
DisclosureSEC source: 0001225208-10-018085 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,415 Underlying: Common Stock · 94 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2010 Filed Jul 16, 2010 20:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 89 | $14.87 | $1,323.43 |
DisclosureSEC source: 0001225208-10-017305 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,321 Underlying: Common Stock · 89 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2010 Filed Jul 1, 2010 20:52 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 107 | $14.26 | $1,525.82 |
DisclosureSEC source: 0001225208-10-016169 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,232 Underlying: Common Stock · 107 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2010 Filed Jun 16, 2010 19:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 87 | $15.52 | $1,350.24 |
DisclosureSEC source: 0001225208-10-015318 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,125 Underlying: Common Stock · 87 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 28, 2010 Filed Jun 1, 2010 21:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 122 | $15.23 | $1,858.06 |
DisclosureSEC source: 0001225208-10-014353 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,038 Underlying: Common Stock · 122 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 14, 2010 Filed May 18, 2010 19:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 428 | $16.20 | $6,933.60 |
DisclosureSEC source: 0001225208-10-013295 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,916 Underlying: Common Stock · 428 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2010 Filed May 3, 2010 19:43 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 85 | $16.72 | $1,421.20 |
DisclosureSEC source: 0001225208-10-011622 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,488 Underlying: Common Stock · 85 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2010 Filed Apr 16, 2010 21:38 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 83 | $16.99 | $1,410.17 |
DisclosureSEC source: 0001225208-10-010501 · doc4.xml · derivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,403 Underlying: Common Stock · 83 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.